RAP-219
Treatment-Resistant Epilepsy / Focal Onset Seizures
Key Facts
About rapport-therapeutics
Rapport Therapeutics is a clinical-stage biotech company founded in 2022 with a mission to develop precision medicines for complex neurological disorders by targeting receptor-associated proteins (RAPs). The company achieved a successful IPO in May 2024, raising significant capital to advance its lead clinical program, RAP-219, for treatment-resistant epilepsy and other indications. Its core strategy leverages a proprietary RAP platform to create neuroanatomically specific therapies, aiming to overcome the pervasive side effects that have plagued central nervous system drug development.
View full company profileAbout rapport-therapeutics
Rapport Therapeutics is a clinical-stage biotech company founded in 2022 with a mission to develop precision medicines for complex neurological disorders by targeting receptor-associated proteins (RAPs). The company achieved a successful IPO in May 2024, raising significant capital to advance its lead clinical program, RAP-219, for treatment-resistant epilepsy and other indications. Its core strategy leverages a proprietary RAP platform to create neuroanatomically specific therapies, aiming to overcome the pervasive side effects that have plagued central nervous system drug development.
View full company profileAbout rapport-therapeutics
Rapport Therapeutics is a clinical-stage biotech company founded in 2022 with a mission to develop precision medicines for complex neurological disorders by targeting receptor-associated proteins (RAPs). The company achieved a successful IPO in May 2024, raising significant capital to advance its lead clinical program, RAP-219, for treatment-resistant epilepsy and other indications. Its core strategy leverages a proprietary RAP platform to create neuroanatomically specific therapies, aiming to overcome the pervasive side effects that have plagued central nervous system drug development.
View full company profile